Acrivon ACR-368 Data Update Pushed to H2 2026, Slightly Delaying Key Catalyst

What happened

Acrivon's Q1 2026 update reaffirms that the registrational-intent ACR-368 Phase 2b study is advancing, but the company now guides a prespecified interim analysis and data update for both all-comer serous endometrial cancer arms in the second half of 2026. This shifts from prior expectations of mid-2026 initial Arm 3 data, suggesting a slight delay or a broader simultaneous data cut. The company maintains its cash runway into Q2 2027, supporting trial execution without near-term financing. However, the update lacks operational details on EU enrollment initiation or screening rates, leaving the throughput thesis unverified. The timeline adjustment extends the wait for confirmatory data, increasing uncertainty and giving bear scenarios more time to unfold.

Implication

The slight delay removes a near-term upside catalyst but may be offset by a more comprehensive simultaneous analysis of both arms. Investors should watch for EU enrollment progress in coming months; failure to show acceleration would heighten dilution risk. The cash runway buffers against financing needs, but the stock remains a binary option with a delayed readout. The thesis still hinges on Arm 3 data quality, but the timeline shift reduces the probability of catalysts within the original 6-month window.

Thesis delta

The shift of the ACR-368 interim analysis to H2 2026 from mid-2026 extends the wait for confirmatory data, lowering near-term catalyst density and modestly increasing bear-case probability, but the overall thesis remains intact pending data.